HHS 📈 Harte Hanks - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4161962026
HHS: Data Analytics, Research, Strategy, Creative Content, Marketing Technology
Harte Hanks, Inc. operates as a customer experience company in the United States and internationally. The company offers data and analytics, including audience identification, profiling, segmentation and prioritization, predictive modeling and data strategy; Research, an understanding of customers, category, competitors, and capabilities; strategy, plans and executes omnichannel marketing, demand generation and customer experience programs; creative and content, including creative concepts, messaging and content assets for print, broadcast, direct mail, website, app, display, social, mobile, search engine marketing, and voice; marketing technology, a website and app development, e-commerce development and enablement, database building and management, platform architecture creation, and marketing automation; digital and multi-channel marketing execution, programs and campaigns across multiple channels, territories, and audiences; demand generation and account based marketing; and managed marketing services. It also provides product, print-on-demand, and mail fulfillment services, including as printing on demand, managing product recalls, and distributing literature and promotional products; custom solutions to engage audiences, target customers, support conferences, and appreciate employees; and third-party logistics and freight optimization services. In addition, the company offers inside sales outsourcing, provides B2B enterprises, and small to midsized businesses with an outsourced sales service; lead generation services; and sales play development, as well as self-service solution through interactive voice response, help centers, online, and via apps and channel technology. It serves B2B, healthcare, pharmaceuticals, health insurance, consumer, travel, hospitality, streaming, entertainment, quick service restaurants, financial, fintech, automotive, and retail markets. The company was founded in 1923 and is headquartered in Chelmsford, Massachusetts. Web URL: https://www.hartehanks.com
Additional Sources for HHS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HHS Stock Overview
Market Cap in USD | 42m |
Sector | Industrials |
Industry | Conglomerates |
GiC Sub-Industry | Advertising |
IPO / Inception | 1993-11-04 |
HHS Stock Ratings
Growth 5y | 24.5% |
Fundamental | -14.6% |
Dividend | 20.4% |
Rel. Strength Industry | -157 |
Analysts | 5/5 |
Fair Price Momentum | 4.58 USD |
Fair Price DCF | 27.21 USD |
HHS Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 67.9% |
HHS Growth Ratios
Growth Correlation 3m | -92.5% |
Growth Correlation 12m | -41.1% |
Growth Correlation 5y | 55.9% |
CAGR 5y | 7.82% |
CAGR/Mean DD 5y | 0.22 |
Sharpe Ratio 12m | -0.64 |
Alpha | -48.10 |
Beta | 1.02 |
Volatility | 40.55% |
Current Volume | 12.9k |
Average Volume 20d | 21.5k |
What is the price of HHS stocks?
As of December 30, 2024, the stock is trading at USD 5.38 with a total of 12,870 shares traded.
Over the past week, the price has changed by +0.37%, over one month by -7.88%, over three months by -27.69% and over the past year by -20.77%.
As of December 30, 2024, the stock is trading at USD 5.38 with a total of 12,870 shares traded.
Over the past week, the price has changed by +0.37%, over one month by -7.88%, over three months by -27.69% and over the past year by -20.77%.
Is Harte Hanks a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Harte Hanks is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.63 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HHS as of December 2024 is 4.58. This means that HHS is currently overvalued and has a potential downside of -14.87%.
Neither. Based on ValueRay Fundamental Analyses, Harte Hanks is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.63 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HHS as of December 2024 is 4.58. This means that HHS is currently overvalued and has a potential downside of -14.87%.
Is HHS a buy, sell or hold?
Harte Hanks has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy HHS.
Harte Hanks has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy HHS.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for HHS stock price target?
According to ValueRays Forecast Model, HHS Harte Hanks will be worth about 5 in December 2025. The stock is currently trading at 5.38. This means that the stock has a potential downside of -7.81%.
According to ValueRays Forecast Model, HHS Harte Hanks will be worth about 5 in December 2025. The stock is currently trading at 5.38. This means that the stock has a potential downside of -7.81%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 17.5 | 225.3% |
Analysts Target Price | 16.5 | 206.7% |
ValueRay Target Price | 5 | -7.8% |